10 completed, 4 terminated. 8 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 5, Terminated 3 |
| Phase 1 | 7 | Completed 6, Terminated 1 |
Follow seribantumab: new trials by email Literature Review of seribantumab trials Research Report on seribantumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab Seribantumab - Metastatic Pancreatic Cancer | Phase 2 | Completed | Ottawa Hospital Research Institute | 1 | 2021-03-29 | 2022-01-12 |
| Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor | Phase 2 | Terminated | Elevation Oncology | 54 | 2020-09-29 | 2025-04-03 |
| Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer Seribantumab, Fulvestrant, Placebo - Metastatic Breast Cancer | Phase 2 | Terminated | Elevation Oncology | 22 | 2017-08-15 | 2020-09-02 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib MM-151, MM-121, MM-141 - Colorectal Cancer, Non-small Cell Lung Cancer | Phase 1 | Terminated | Merrimack Pharmaceuticals | 5 | 2015-08-01 | 2017-09-05 |
| A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC MM-121, Docetaxel - Non-Small Cell Lung Cancer, NSCLC | Phase 2 | Terminated | Elevation Oncology | 153 | 2015-02-01 | 2021-10-12 |
| A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers MM-121 (SAR256212), SAR245408 - Solid Tumor Cancers | Phase 1 | Completed | Sanofi | 26 | 2011-11-01 | 2014-06-13 |
| A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers MM-121, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Merrimack Pharmaceuticals | 223 | 2011-10-01 | 2016-05-12 |
| A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers MM-121, Irinotecan, Cetuximab - Colorectal Cancer, Squamous Cell Head and Neck Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 48 | 2011-10-01 | 2016-09-08 |
| Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors MM-121, Carboplatin, Pemetrexed - Solid Tumors | Phase 1 | Completed | Merrimack Pharmaceuticals | 43 | 2011-10-01 | 2016-09-14 |
| A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer MM-121, Paclitaxel - ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients | Phase 2 | Completed | Merrimack Pharmaceuticals | 196 | 2011-08-01 | 2016-05-03 |
| A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers MM-121, Paclitaxel - Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 41 | 2010-10-01 | 2016-09-08 |
| Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer MM-121, Placebo, Exemestane - Her2 Negative Breast Cancer Patients | Phase 2 | Completed | Merrimack Pharmaceuticals | 118 | 2010-06-01 | 2016-05-12 |
| A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer MM-121, Erlotinib - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Merrimack Pharmaceuticals | 162 | 2010-02-01 | 2016-08-22 |
| Phase I Safety Study of the Drug MM-121 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment MM-121 - Advanced Solid Tumors | Phase 1 | Completed | Merrimack Pharmaceuticals | 44 | 2008-07-01 | 2016-09-01 |
Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Fibromatosis, Gingival, 2 (2) · Head and Neck Neoplasms (2) · Lethal Congenital Contracture Syndrome 2 (2) · Lung Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Bile Duct Neoplasms (1) · Carcinoma, Ovarian Epithelial (1)
Merrimack Pharmaceuticals (9) · Elevation Oncology (3) · Ottawa Hospital Research Institute (1) · Sanofi (1)
United States (13) · Canada (6) · Germany (4) · Spain (4) · France (2) · South Korea (2) · Australia (1) · Austria (1) · Belgium (1) · Hungary (1) · Russia (1) · Taiwan (1)
Victor Moyo, MD (6) · Akos Czibere, MD, PhD (1) · Crystal Denlinger, MD (1) · Keedy L Vicki, MD (1) · Kwok Kin Wong, MD (1) · Marc Pipas, MD (1)
PMID 27998236, PMID 30975923, PMID 34250553, PMID 41428976
2017 (1)